For UK pharmaceutical and life sciences leaders
You're spending heavily on KOL engagement but cannot prove it moves prescribing behaviour
Without a robust framework connecting advocacy activity to prescribing patterns, budget continues to flow into relationships that may carry little measurable influence. Fragmented data keeps the gap invisible.
Two minutes. Solva follows up with specific KOL measurement options.
- Marketing campaigns failing to achieve anticipated market share gains despite significant KOL investment
- Medical Science Liaisons (MSLs) struggling to demonstrate the value of their interactions to commercial teams
- Difficulty in identifying the most influential KOLs for specific therapeutic areas or product launches
- Inability to adapt KOL engagement strategies quickly in response to market shifts or competitor activities.
- Inefficient allocation of Medical Affairs and marketing budgets
- Delayed or suboptimal product launches due to unoptimized KOL advocacy
- Millions in wasted marketing and medical affairs spend on ineffective KOL programs
- Reduced return on investment (ROI) for new drug development and market access initiatives
- Perception of pharmaceutical companies as lacking data-driven decision-making
- Erosion of trust among HCPs if KOL engagement is perceived as purely transactional rather than scientific exchange
Only 24% of pharma companies comprehensively analyze HCP engagement data, and less than 20% measure knowledge gain from these interactions (EPG Health, 2023)
Frequently asked questions
Why does this problem persist?
Many pharmaceutical companies struggle with fragmented data and a lack of robust analytical frameworks to track the true influence of KOL engagement. This leads to an inability to connect advocacy activities with tangible business outcomes, making it difficult to optimize strategies and demonstrate ROI.
What is the cost of leaving it unaddressed?
Structured KOL engagement programs can reduce overall promotional expenditure by 26.8% (Journal Of Multidisciplinary, 2025)
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.